Current Clinical Trials

Current Clinical Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Two Fixed Doses Of Tavapadon In Early Parkinson’s Disease (TEMPO-1 TRIAL).

Summary: The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.

https://clinicaltrials.gov/ct2/show/NCT04201093

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Tavapadon As Adjunctive Therapy For Parkinson’s Disease In Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 TRIAL)

Summary: The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of “on” time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson’s Disease (PD) who are experiencing motor fluctuations.

https://clinicaltrials.gov/ct2/show/NCT04542499

Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson’s Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications

Summary: This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

https://clinicaltrials.gov/ct2/show/NCT04857359?lead=Addex&draw=2&rank=1

Conducting Clinical Trials

Please complete the below Clinical Trial Risk Assessment Questionnaire if you are interested in conducting a clinical trial at Roseman University.